ShenZhen GTJA Investment Group
63
29M
55
2.74
16
0.13
6
- Stages of investment
- Areas of investment
Summary
ShenZhen GTJA Investment Group is the famous VC, which was founded in 2001. The fund was located in Asia if to be more exact in China. The leading representative office of defined VC is situated in the Shenzhen.
The fund has exact preference in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Pharmaceutical, Therapeutics. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight Shanghai Henlius, Mabworks, Akeso Biopharma.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the ShenZhen GTJA Investment Group, startups are often financed by V Star Capital, Northern Light Venture Capital, Initial Capital. The meaningful sponsors for the fund in investment in the same round are V Star Capital, Shenzhen Capital Group, SBCVC. In the next rounds fund is usually obtained by Shenzhen Capital Group, Loyal Valley Capital, GSR Ventures.
Considering the real fund results, this VC is 53 percentage points more often commits exit comparing to other organizations. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2018. The usual things for fund are deals in the range of 50 - 100 millions dollars. The average startup value when the investment from ShenZhen GTJA Investment Group is 500 millions - 1 billion dollars.
The current fund was established by Dajian Cai. Besides them, we counted 1 critical employee of this fund in our database.
Investments analytics
Analytics
- Total investments
- 63
- Lead investments
- 16
- Exits
- 6
- Rounds per year
- 2.74
- Follow on index
- 0.13
- Investments by industry
- Health Care (32)
- Biotechnology (24)
- Pharmaceutical (21)
- Medical (14)
- Biopharma (8) Show 55 more
- Investments by region
-
- China (60)
- United States (3)
- Peak activity year
- 2017
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Avg. valuation at time of investment
- 76M
- Group Appearance index
- 0.57
- Avg. company exit year
- 18
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| al+ | 10 Oct 2017 | Software, Analytics, Artificial Intelligence, Machine Learning | Early Stage Venture | 5M | Chiba Prefecture, Tateyama, Japan |
| Shanghai Henlius Biotech | 22 Dec 2017 | Biotechnology, Health Care, Medical, Pharmaceutical | Early Stage Venture | 190M | Shanghai, China |
| 15 Sep 2019 | SaaS, Productivity Tools | Seed | 204K | Barcelona, Catalonia, Spain | |
| Yunshan Medical | 29 Dec 2017 | Internet, Health Care, Health Diagnostics, Wellness | Early Stage Venture | 20M | Shenzhen, Guangdong, China |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.